Richard Hendriks, Ph.D.
“With the realization of diverse disciplines like Nano-biotechnology, Biomaterials, Implants, Tissue Engineering, and Genomics, it is an interesting time to be an Analyst at Nerac.”
Analyst Richard Hendriks, Ph.D., partners with pharmaceutical and biotech companies to discover the most effective ways of meeting their business goals. This encompasses a range of solutions from innovations in biotechnology to analytical assessments of recent treatment advances.
Qualitative analyses of citation and patent literature is the foundation of such endeavors, and Dr. Hendriks has specialized in this area for over 15 years with Nerac. During that time, he has gained significant industry and government insight. He has a Ph.D. in neuroscience from University of Melbourne, Australia, and a background in neuronal electrophysiology. During his research career, Dr. Hendriks received several grants and fellowships from the National Institutes of Health and the National Science Foundation. He was a principal investigator for early collaborative research with Sandoz that focused on neuronal receptor pharmacology for a compound that was eventually commercialized as Tropisetron. His subsequent research focused on the central nervous system and included an investigation into the role of potassium channels in embryonic neuronal migration as part of an investigation into potential cures for deafness during a research affiliation with Yale Medical School of New Haven, CT. Dr. Hendriks has authored several published articles and abstracts on physiology and electrophysiology. He has also worked for the USPTO, successfully examining over 800 PCT patent applications, in the field of Medical Devices. As such, he has expertise in prior art searching, medical devices, claim structure, and the use of patent search engines. Overall, Dr. Hendriks’ areas of proficiency within Nerac include; intellectual property, medical devices, pharmacovigilance, toxicology, pharmacology, drug development, electrophysiology, bioengineering and neurotransmitters.
Primary Disciplines
- Pharmaceuticals
- Drug Safety
- Intellectual Property
- Neuroscience
- Medical Devices
- Pharmacology and neuropharmacology
- Drug development
- Bioengineering
Industries
- Pharmaceuticals
Credentials
- Ph.D., Neuroscience, University of Melbourne, Australia
- B.Sc., Hons, Medical Physiology, Flinders University of South Australia
- B.Sc., Biophysics, Flinders University of South Australia (FUSA)
Published
NIH, National Institute on Deafness and Communicative Disorders (NIDCD) T32 DC00025-12: from 8-1-94 to 8-1-96. “Communicative Disorders: Cellular and Neural Biology.” Role: Principal Investigator
NIH, National Institute on Deafness and Communicative Disorders (NIDCD) F32 DC00267-01: from 12-1-96 to 12-1-97. “Role of potassium channels in neuronal migration”. Role: Principal Investigator
NIH, National Institutes of Health, RO1 from 1-1-99 to 12-31-01. “Prenatal Protein Malnutrition and Hippocampal Plasticity.” Role: Research Associate
NIH, National Institutes of Health, R21, Technology Grant 1-1-2000 to 12-31-2001″Neurophysiology of the Developing Hippocampus” Role: Research Associate
NSF, National Science Foundation, RU1, . 6-15-99 –6-15-2002. “ Noradrenergic changes associated with hippocampal LTP in the freely moving male and female rat.” Role: Research Associate
NIH, National Institutes of Health, R15, AREA GRANT. 1-1-2000 to 12-31-2001″Neurophysiology of the Developing Hippocampus” Role: Research Associate
Publications
Hendriks, R, “Spinal Cord Stimulation and Parkinson’s Disease”, Nerac Insights, https://www.nerac.com//nerac_insights.php?category=articles&id=180, April 2009
Hendriks, R, “Neuroscience and Carbon Nanotubes”, Nerac Insights, https://www.nerac.com//nerac_insights.php?category=articles&id=179, April 2009
Hendriks, R, “Risk Assessment: Nerac develops methodology to assess drug and technology success potential”, Nerac Insights, https://www.nerac.com//nerac_insights.php?category=articles&id=129, October 2008
Hendriks, R, “Patent News: Retinal implants open the shutters on blindness”, SPIE, http://spie.org/x34979.xml?ArticleID=x34979, May 1, 2009
Hendriks, R, “Off the Label: Contrary to Reports, FDA Guidelines for Off-Label Promotion Tighten Loopholes”, Nerac Insights, https://www.nerac.com//nerac_insights.php?category=articles&id=14, March 2008
Hendriks, R, “Pharma’s Strategic Outlook: Conference Buzz in New York Centers on Alliances and M&A Activity”, Nerac Insight, https://www.nerac.com//nerac_insights.php?category=articles&id=16, March 2008
Hendriks, R, “Bionic Eyes: Retinal Implants, Still in their Infancy, Provide a New Vision of the Future”, Nerac Insights, https://www.nerac.com//nerac_insights.php?category=articles&id=35, March 2008
Bronzino, JB, Kehoe, P, Hendriks, R, Vita, L, Golas, B, Vivona, C and Morgane, PJ, “Hippocampal Neurochemical and Electrophysiological Measures from Freely Moving Rats”, Exp. Neurol. 155: 150-155, 1999
Morest, DK, Hendriks, R, Kaczmarek, LK, “Role in neuronal cell migration for high-threshold potassium currents in the chicken hindbrain”, Journal of Neuroscience Research 58 (6) 805-814, 1999
Morest, DK, Hendriks, R, Kaczmarek, LK, “Shaw-like potassium currents in the auditory rhombencephalon throughout embryogenesis”, Journal of Neuroscience Research 58 (6) 791-804, 1999
Kunze, WAA, Bornstein, JC, Furness, JB, Hendriks, R, and Stephenson, D.S.H.. “Charybdotoxin and iberiotoxin but not apamin abolish the slow afterhyperpolarization in myenteric plexus neurons”, Pfluger’s Arch. 428: 300-306, 1994